Moderna — Moderna soared 23% after the drug maker reported “positive data” for its coronavirus vaccine. The early-stage human trial showed the vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday. At day 43, about two weeks after the second dose was given to participants, levels of antibodies were at the levels generally seen in blood samples from people who recovered from the disease.
